Insider trade

Serina Therapeutics (SER): Chief Scientific Officer sold ~$24K

Randall Moreadith, Chief Scientific Officer at Serina Therapeutics, sold ~$24K of Serina Therapeutics shares.

~$24K
Approx. value · 6,500 sh @ $3.75
Traded
Nov 18, 2025
Filed
Nov 19, 2025

What stands out in this filing

  • The sale emptied this holding: the filing reports no shares left in it afterwards.
  • 6,500 shares at an average of $3.75 each, as reported on the form.
  • Filing box checked: sold under a Rule 10b5-1 plan.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 13, 2025InsiderOfficer sold ~$22K of SER shares in the open market
  2. Oct 20, 2025InsiderOfficer sold ~$32K of SER shares in the open market
  3. Oct 27, 2025InsiderOfficer sold ~$4.9K of SER shares in the open market
  4. Oct 28, 2025InsiderOfficer sold ~$28K of SER shares in the open market
  5. Nov 5, 2025InsiderOfficer sold ~$14K of SER shares in the open market
  6. Nov 10, 2025InsiderOfficer sold ~$27K of SER shares in the open market
  7. Nov 13, 2025Company filing · Form 8-K · ResultsReported its results
  8. Nov 18, 2025 · this disclosureInsiderOfficer sold ~$24K of SER shares in the open market

What came next

  1. Nov 24, 2025InsiderOfficer sold ~$2.1K of SER shares in the open market
  2. Nov 25, 2025InsiderOfficer sold ~$23K of SER shares in the open market
  3. Dec 2, 2025InsiderOfficer sold ~$5.9K of SER shares in the open market
  4. Dec 3, 2025InsiderOfficer sold ~$18K of SER shares in the open market
  5. Dec 9, 2025InsiderOfficer sold ~$2K of SER shares in the open market
  6. Dec 10, 2025InsiderOfficer sold ~$2.2K of SER shares in the open market
  7. Dec 11, 2025InsiderOfficer sold ~$12K of SER shares in the open market
  8. Dec 12, 2025InsiderOfficer sold ~$5.5K of SER shares in the open market
  9. Dec 16, 2025InsiderOfficer sold ~$9.6K of SER shares in the open market
  10. Dec 22, 2025InsiderOfficer sold ~$15K of SER shares in the open market
  11. Dec 23, 2025InsiderOfficer sold ~$11K of SER shares in the open market
  12. Jan 9, 2026Company filing · Form 8-K · Listing notice, Reg FDReceived a notice from its stock exchange, and shared information with investors“On January 9, 2026, Serina Therapeutics, Inc. (the “Company”) received a notification (the “Letter”) from The NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the minimum stockholders’ equity requirements of Sections 1003(a)(i), 1003(a)(ii), and 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”) requiring stockholders’ equity of (i) $2.0 million or more if…”
  13. Jan 13, 2026InsiderOfficer sold ~$14K of SER shares in the open market
  14. Jan 14, 2026InsiderOfficer sold ~$2.7K of SER shares in the open market
  15. Jan 20, 2026InsiderOfficer sold ~$6.1K of SER shares in the open market
  16. Jan 21, 2026InsiderOfficer sold ~$6K of SER shares in the open market
  17. Jan 22, 2026InsiderOfficer sold ~$7.4K of SER shares in the open market
  18. Jan 28, 2026InsiderOfficer sold ~$23K of SER shares in the open market
  19. Feb 2, 2026InsiderOfficer sold ~$20K of SER shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Serina Therapeutics

OQRO holds no insider, Congress, fund or contract record for Serina Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its SER page.

Other recent filings by Randall Moreadith, Chief Scientific Officer

The full history of Randall Moreadith, Chief Scientific Officer is on the profile page.

How this filing works

Explore the data

Common questions

Which Serina Therapeutics (SER) insider traded, and how much?

Randall Moreadith, Chief Scientific Officer at Serina Therapeutics, sold ~$24K of Serina Therapeutics shares. 6,500 shares at $3.75.

When did it happen, and when was it made public?

Traded: Nov 18, 2025. Filed: Nov 19, 2025. That is 1 day between the two dates.

What stands out in this filing?

The sale emptied this holding: the filing reports no shares left in it afterwards. 6,500 shares at an average of $3.75 each, as reported on the form. Filing box checked: sold under a Rule 10b5-1 plan.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

Does this mean SER stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Serina Therapeutics

Everything OQRO holds on this company is on its SER page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data